Brinsupri (brensocatib) is a dynamic, targeted therapy that disrupts the core inflammatory cycle of Non-Cystic Fibrosis Bronchiectasis (NCFB).
To create a visual representation of how this drug works, we must understand the precise mechanism it targets within the disease process. The data below is tailored to guide the creation of four distinct graphics that explain the pathology and Brinsupri’s clinical success.
1. Disease Process: The “Vicious Vortex”
The core problem in NCFB is a self-sustaining cycle that damages the lungs.
| Step in Vortex | Visual Element for Graphic | Key Data to Include |
| 1. Trigger | An initiating event: e.g., a severe infection (pneumonia) or an underlying immune issue. | “Initial Lung Injury” |
| 2. Impaired Clearance | Airway diagram showing damaged cilia (hair-like structures) and thick, settled mucus. |
“Ciliary Dysfunction” “Mucus Plugging” |
| 3. Bacterial Colonization | Icons representing bacteria growing within the trapped mucus. | “Chronic Infection” (e.g., P. aeruginosa) |
| 4. Neutrophil Influx | Large white blood cells (neutrophils) swarming the area from blood vessels. | “Massive Neutrophil Infiltration” |
| 5. Protease Release | Visualizing “molecular scissors” (NSPs) being released by neutrophils, shredding the airway wall. | “Excessive Release of NSPs” (e.g., Neutrophil Elastase) |
| 6. Structural Damage | Airway shown becoming permanently dilated, flabby, and scarred. | “Permanent Airway Dilation (Bronchiectasis)” |
2. Treatment Options
Management generally falls into two categories: daily clearing (removing the mucus) and inflammation control (preventing the damage).
i. Airway Clearance Techniques (ACT)
The “Gold Standard” for daily care. These techniques move mucus from small airways to larger ones so you can cough it up.
- PEP Devices: Handheld tools (like Acapella) that create vibrations to loosen mucus.
- Active Cycle of Breathing (ACBT): A specific sequence of deep breaths and “huffs.”
- Hydration: Drinking plenty of water keeps mucus thin and easier to move.
ii. Disease-Modifying Therapy: Brinsupri
Approved in 2025, Brinsupri (brensocatib) is the first medication designed to stop the cycle of inflammation in non-cystic fibrosis bronchiectasis.
- How it Works: It blocks an enzyme (DPP1) that activates aggressive white blood cells in the lungs. By “turning down the volume” on this inflammation, it helps prevent the scarring that leads to widened airways.
- The Goal: Clinical trials showed a 20% reduction in yearly flare-ups and a slower decline in lung function.
- Usage: A single tablet taken once daily. Note that while taking this, you should maintain excellent dental hygiene and avoid “live” vaccines.
3. Clinical Success: Rate of Flares (ASPEN Study)
The most robust data supporting Brinsupri comes from the Phase 3 ASPEN trial. This section is ideal for showing effectiveness over a full year of treatment (52 weeks).
Reductions in Annualized Exacerbations (Flares)
A standard bar chart can illustrate this reduction.
| Treatment Group | Mean Annual Flares | Reduction vs. Placebo | Statistical Significance |
| Placebo (Standard Care) | 1.29 | — | — |
| Brinsupri 10 mg | 1.02 | 21.1% Reduction | p=0.004 |
| Brinsupri 25 mg | 1.04 | 19.4% Reduction | p=0.005 |
Median Time to First Flare (Kaplan-Meier Curve)
A Kaplan-Meier curve is a classic clinical trial graphic showing “survival” from an event (in this case, surviving without a flare).
-
Placebo: 50% of patients had their first flare by 37 weeks.
-
Brinsupri 25 mg: 50% of patients had their first flare by 51 weeks.
-
Visual Interpretation: The Brinsupri line would stay significantly higher than the placebo line, demonstrating that patients on the drug remained flare-free for much longer.
4. Clinical Success: Lung Function Protection
The most striking finding of the ASPEN trial—specific to the 25 mg dose—was its ability to slow down the loss of lung function (FEV1), a marker of disease progression.
The Impact on FEV1 Decline (mL/year)
This data should be presented in a bar chart, contrasting the “steep decline” of placebo with the “preserved function” of the higher dose.
-
Placebo Group: Average decline of 62 mL/year.
-
Brinsupri 25 mg Group: Average decline of only 24 mL/year.
The Key Visual Metric: This represents a 61% reduction in the rate of lung function loss. Brinsupri 25 mg is not just treating symptoms; it is preserving the patient’s long-term lung health by dramatically slowing the disease’s “vicious vortex.”
5. Recognizing a “Flare-Up” (Exacerbation)
Even with modern treatments like Brinsupri, infections can still occur. Contact your medical team if you notice:
- Mucus Changes: If it becomes thicker, darker (yellow/green), or much more plentiful.
- Increased Breathlessness: Feeling winded during tasks that are usually easy.
- Fever or Chills: Signs of an active infection.
- Hemoptysis: Seeing blood in your mucus (requires prompt medical attention).
6. Daily Health & Prevention
- Vaccinations: Keep up with flu, COVID-19, and pneumonia shots.
- Exercise: Pulmonary rehab or regular walking helps keep lungs expanded.
- Avoid Irritants: Stay clear of smoke, strong fumes, and high-pollution areas.